Efficacy observation on the treatment of a novel regimen based on boanmycin for patients with refractory non-Hodgkin lymphoma

( views:149, downloads:0 )
Author:
CHEN Xi-lin(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
ZHANG Wei-jing(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
DA Yong(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
XIAO Xiu-bin(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
ZHAO Shi-hua(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
WANG Shuang(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
YANG Qiu-shi(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
SHAO Lan-lan(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
YANG Yi-xin(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
SU Hang(Department of Lymphoma,Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China)
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
Volume 20, Issue 10, 2011
DOI:
10.3760/cma.j.issn.1009-9921.2011.10.006
Key Word:
Lymphoma, non-Hodgkin;Drug therapy, combination;Boanmycin

Abstract: Objective To observe the activity and safety of a novel combination therapy for patients with recurrent or refractory aggressive non-Hodgkin lymphoma (NHL).Methods Six consecutive patients with recurrent or refractory aggressive NHL were treated with B-VIP regimen,boanmycin (5 mg/m2 on Days 1,4,8,12 and 15),vincristine (1.4 mg/m2 on Days 1,8 and 15),ifosfamide (1.2 g/m2 on Days 1,2,3 and 15,16,17) and prednisone (50 mg on Days 1 to 10),every 21 days.All the patients had received ≥5 cycles (average 8.3 cycles) of previous chemotherapy.Results Six patients (100 %) were evaluable for response.The overall objective response rate was 66.7 % (4 patients),including 1 case complete (CR) and 3 cases partial responses.Myelosuppression was the most frequent serious complication of this regimen.Conclusion In the current study,B-VIP was a highly active and safe combination therapy for patients with refractory disease with a poor prognosis or for patients with multiply recurrent aggressive NHL.

  • [1]Messori A,Trippoli S,Valani M,et al.Survival in patients with intermediate or high grade non-Hodgkin's lymphoma:meta-analysis of randomized studies comparing third generation regimens with CHOP.Br J Cancer,2001,84:303-307.
  • [2]侯淑玲,张巧花.2009年美国血液学年会难治性淋巴瘤治疗进展的热点简介.白血病·淋巴瘤,2010,19:102-103.
  • [3]Harting R,Venugopal P,Gregory SA,et al.Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Clin Lymphoma Myeloma,2007,7:406-412.
  • [4]Atta J,Chow KU,Weidmann E,et al.Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.Leuk Lymphoma,2007,48:349-356.
  • [5]Steingass SK.Hematopoietic cell transplantation in non-Hodgkin's lymphoma.Semin Oncol Nurs,2006,22:107-116.
  • [6]Musolino A,Perrone MA,Michiara M,et al.Lomustine[chloroethylnitrosourea (CCNU)],ifosfamide,bleomycin,vincristine,and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive nonHodgkin lymphoma.Cancer,2005,103:2109-2117.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn